MedTrace Logo

An Observational Study of Tarceva (Erlotinib) in Patients With Non-Small Cell Lung Cancer

NCT01488331 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 217

Last updated 2016-11-02

No results posted yet for this study

Summary

This prospective, multi-center, observational study will assess the progression-free survival and safety of patients with locally advanced or metastatic non-small cell lung cancer treated with Tarceva (erlotinib) and not disease progressing after at least 9 months. Data will be collected for 24 months.

Conditions

  • Non-Squamous Non-Small Cell Lung Cancer

Sponsors & Collaborators

Principal Investigators

  • Clinical Trials · Hoffmann-La Roche

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-06-30
Primary Completion
2013-11-30
Completion
2013-11-30

Countries

  • France

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01488331 on ClinicalTrials.gov